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Abstract
Purpose. Rhabdomyosarcoma (RMS) is an embryonal tumor thought to arise from skeletal muscle cells that fail to
differentiate terminally. The majority of RMSs express MyoD, a protein essential to the differentiation of skeletal muscle.
It was recently shown that during myogenesis, MyoD activates the expression of the cyclin-dependent kinase inhibitor
(CDKi), p21, which itself plays a critical role in normal muscle development. To investigate the integrity of the MyoD/p21
pathway in RMS, we analyzed p21 and its relationship to MyoD expression in RMS.
Methods. A panel ofRMS samples was assembled from primary biopsies and from cell lines. Integrity ofp21 was analyzed
by single-strand conformation polymorphism (SSCP) and sequencing. Expression of p21 and MyoD was determined by
Northern blot analysis, and the ability of exogenous p21 to arrest the cell cycle of RMS cell line was determined by
transfection studies.
Results. Our analysis indicates that although p21 is wild type in RMS, there is an inverse correlation between the levels
of p21 and MyoD in these tumors. Tumors that express significant amounts ofMyoD fail to express p21. This does not
appear to be the result of mutations within the potential CACGTG sites present in the p21 promoter region or in the
coding region of p21. An additional group of RMSs express very high levels of p21 but express little, if any, MyoD.
Furthermore, RD, a RMS cell line which expresses high levels of endogenous p21, undergoes withdrawal from the cell
cycle following forced expression of p21, suggesting that the pathway which would lead to G1 arrest from endogenous p21
activity is defective.
Discussion. These data suggest that the interaction between p21 and MyoD is defective in RMS although the precise
nature of the defect remains to be elucidated.
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Introduction
Rhabdomyosarcoma (RMS) is the most common
soft tissue sarcoma in children and comprises 5-8%
of all pediatric tumors. This embryonal tumor is
thought to arise from poorly differentiated mes-
enchymal cells, with morphologic and biochemical
similarities to primitive skeletal muscle cells. These
tumors behave in an aggressive fashion, have a high
proliferative capacity and fail to differentiate into
mature muscle cells.
The mechanisms involved in the regulation of
skeletal muscle differentiation have been investi-
gated intensively. The pathways which lead to ter-
minal differentiation appear to be coupled to those
which cause withdrawal from the cell cycle and,
presumably, this allows cells to maintain a differen-
tiated state. The closely related processes of ter-
minal differentiation and growth arrest are tightly
regulated through complex mechanisms involving
cyclins, cyclin-dependent kinases (CDK’s) and
CDK inhibitors (CDKI’s).
2 Basic helix-loop-helix
(HLH) transcription factors in the MyoD family
induce expression of skeletal muscle specific
proteins and withdrawal from the cell cycle.
3
Recently, this process has been shown to be associ-
ated with the induction of p21 (WAF1/Cipl), 4,5 a
potent CDKI. Furthermore, MyoD has been shown
to induce the expression of p21 directly, suggesting
a direct relationship between terminal muscle differ-
entiation and growth arrest.
An early event in the transformation process in
RMS may be related to the dysregulation of the
normally tightly coupled pathways of muscle differ-
entiation and growth arrest. RMSs are known to
express MyoD or other related HLH proteins,
6 yet
retain their ability to proliferate and fail to differen-
tiate terminally. It has been shown that MyoD
derived from RMS cell lines is capable of binding to
its cognate DNA sequences, but is unable to trans-
activate muscle-specific genes, suggesting that RMS
cells are deficient in a factor required for MyoD
activity.
7 Since MyoD activates the expression of
p21 in normal developing muscle, and since we
recognized the presence of potential HLH binding
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Table 1. Rhabdomyosarcoma cell lines and tumors
Expression Expression
Sample Histology ofMyoD of p21 p53 status
Cell lines
Tumors
RD Embryonal + + + +
RH18 Mixed Alveolar/Embryonal + + + +
RH28 Alveolar ND ND
RH30 Alveolar + + + +
CTR Embryonal + + + +
PO49 Alveolar + +
PO50 Alveolar + + + + + +
PO51 Alveolar ND ND
PO52 Alveolar + +
9003 Embryonal ND ND
I-12 Alveolar + + + +
5700 ND + + + +
SWMC Embryonal ND ND
I-174 Alveolar + +
Mutation Arg Trp Codon 248
WT
WT
Mutation Arg Ser Codon 280




Abbreviations: ND, not determined; WT, wild type; + + +, high expression; +, low expression.
sites in the promoter sequence of p21,
8 it was of
interest to determine whether expression of MyoD
coincides with expression of p21 in RMS. In
addition, we also investigated the integrity of the
p21 G1 arrest pathway in RMS by analyzing the
primary structure of p21 in RMS and the ability of
exogenous p21 to cause forced withdrawal of RMS
cells from the cell cycle.
Patients and methods
Cell lines and tumor samples
Tumor histology and p53 status are described in
Table 1. All tumor tissues were obtained from the
Cooperative Human Tissue Network and had been
confirmed to contain viable tumor. Tumor samples
PO49, PO50, PO51, PO52, 5700, 1-174 and 1-12
are all alveolar RMSs. SWMC and 9003 are embry-
onal RMSs. RD is a human embryonal RMS cell
line obtained from the American Type Culture Col-
lection (ATCC).
9 RH18, RH28 and RH30 are
human RMS cell lines established from mixed
embryonal/alveolar (RH18) and alveolar (RH28,
RH30) RMS and obtained from Dr Peter Houghton
(St Jude Children’s Research Hospital). CTR is a
human embryonal RMS cell line established and
supplied by C. P. Reynolds (Department of Pedi-
atrics, University of Southern California). Cells
were grown at 37C in 95% air/5% CO2 in RPMI
1640 containing 10% heat-inactivated fetal calf
serum (FCS), 2 mM L-glutamine, 50 pg m1-1
penicillin and 50 #g ml-1 streptomycin.10 All tissue
culture products were obtained from Bio-Whittaker
(Walkersville, MD, USA).
RNA isolation and Northern analysis
Total cellular RNA was extracted from cell lines and
tumor specimens as previously described. 11 RNA
was quantitated using UV spectrophotometry at
A 260 nm. Equal amounts of RNA were elec-
trophoresed in a 1.2% agarose/2.2% formaldehyde
gel, transferred to a nylon membrane and hybridized
with 32P-labeled (Random prime labeling: Prime-It,
Stratagene, La Jolla, CA, USA) probes for p21
cDNAlz and for Myo D.
13
Plasmid constructs
The pCEP4 expression vector (Invitrogen, San
Diego, CA, USA) was used to prepare constructs
containing the following cDNAs as previously
described:
lz (1) full-length wild-type p21 cDNA; (2)
full-length p21 cDNA in an anti-sense orientation;
(3) a mutant full-length p21 cDNA, with a mutation
at codon 63 (Phe to Leu).
Transfections
p21 sense, p21 anti-sense or mutant p21 constructs
were transfected into the RMS cell line RD using
calcium phosphate precipitation as previously
described.
14 Transfection with vector alone served
as control. All transfection experiments were done
in triplicate. Briefly, 5 105 cells were plated in
six-well tissue culture plates, incubated overnight at
37C and washed with fresh medium 3 h prior to
transfection. Plasmid (1 #g) and 4 #g of salmon-
sperm carrier DNA were used for transfection in
each well. After transfection, the cells were incu-
bated for 12 h at 37C, washed and fed with fresh
medium (RPMI 1640 supplemented with 10%
FCS). After 24 h, transfectants were selected in
medium containing hygromycin (500 #g ml-1), and
growth of colonies was monitored daily for a period
of 2 weeks. The plates were then stained with crystal
violet and the colonies were counted by two inde-
pendent observers. In separate experiments, follow-
ing transfection and selection of colonies in
hygromycin-containing medium, cells were
trypsinized and counted directly by the trypan blue
exclusion method.PCR-SSCP-p21
PCR-SSCP analysis
1 was used to screen for muta-
tions in the coding region of p21 as previously
reported.
1 In addition, we designed primers to ana-
lyze the promoter region for p21 by SSCP,
8
specifically including a region which contains the
sequence CAGCTG, a consensus binding sequence
for HLH proteins (E box).
16 Briefly, DNA was
extracted from cell lines and tissue samples of RMS
using standard methods. The coding region of the
p21 gene was amplified using oligonucleotide
primers to generate four fragments(2.1, 2.2, 2.3, 3)
(Fig. 1). The primers used were: region 2.1: WAF
1, 5’-AGAGGAGGCGCCATGTCAGAA; WAF
1.1-3R, 5’AGGTAGAGCTTGGGCAGGCC;
region 2.2: WAF 1.25F, 5’-CGAGACACCACTG-
GAGGGTG; WAF 1.2R, 5’-CTTCAGCCT-
GCTCCCCTG; region 2.3: WAF 2.3.5,
5’-TGGACCTGTCACTGTCTT; WAF 2.3.3, 5’-
TGAGAATCCTGGTCCCTT; Region 3: WAF
3b5, 5’-GATTTCTACCACTCCAAA; WAF RT3,
5’-GGCCTTTGAG GCCCTCGCGCTT.
Primers for the promoter region were: PROM-5,
5’-GAGGGAGGTCCCGGGCG; PROM-3, 5’-
AATCCGCGCCCAGCTCCG. Radiolabeled PCR
products were separated on a 1X MDE gel
(Hydrolink, Malvern, PA, USA) at 12 W, constant
power, at room temperature, for 12-18 h. A nega-
tive control and a blank PCR (reaction without
template) were always included in the analysis to
confirm the absence of exogenous contamination.
PCR products with abnormal migration were
sequenced using the Sequenase method (USB/
Amersham, Cleveland, OH, USA).
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parison, in normal, terminally differentiated adult
skeletal muscle (Fig. 2, lane 1), modest levels of
MyoD expression are associated with high levels of
p21 mRNA expression. In contrast, tumors with
similar, or higher, MyoD expression levels (samples
2 3 4 5 6 7 8 9 10 11
2: 3 4 5 6 7 8 9 10 11
::E :3::: 0 0
28S
18S
Fig. 1. Structure ofthe coding regionforp21 and regions used
for amplification in SSCP analysis. Abbreviations: aa, amino
acid; bp, base pair; WAF p21.
Results
Expression ofp21 and MyoD
We first sought to determine whether MyoD
expression in .RMS tumors parallels p21 expression
as would be predicted. Ten samples of RMS
(including four cell lines and six fresh tumor biop-
sies) were analyzed for expression of p21 and MyoD
by Northern blot analysis. Expression of p21 was
highly variable (Fig. 2). The cell lines RD and
RH18, and tumors 5700 and PO50, expressed high
levels of p21, whereas the cell lines CTR and RH30,
and tumor samples 1-12, 1-174, PO49 and PO52,
expressed low levels of p21. Expression of MyoD
was also variable. High levels of expression were
seen in cell lines RH30 and CTR, and in tumor
samples 1-12 and PO50. In contrast, low levels of
MyoD expression were seen in cell lines RD and
RH18, and in tumor samples 1-174, PO49, PO52
and 5700 (Fig. 2). Thus, in the majority of the
samples, there was an inverse relationship between
expression of p21 and MyoD, such that cell lines
and tumors which expressed high levels of MyoD












Fig. 2. Northern blot analysis of the expression ofp21 and
MyoD inRMS tumors and cell lines: (a) expression ofp21; (b)
expression of MyoD; (c) ethidium bromide stained gel for
comparison ofRNA amounts.138 M. Weintraub et al.
Fig. 3. SSCPanalysisfor the coding region ofp21: (a) region
3; (b) region 2.2. Samples P049 and P052 show an aberrant
conformer in both regions. Abbreviation: WT, wild type.
RH30, CTR, PO52, 1-12, Fig. 2), express low levels
of p21. A second group of RMS tumors and cell
lines expresses high levels of p21 but no detectable
levels of MyoD mRNA.
SSCP analysis
Since high levels of p21 mRNA expression were
found in several cell lines and tumors, we sought to
determine whether the primary structure of p21 was
altered. SSCP analysis of the p21 coding region was
performed in 12 RMS samples (four cell lines and
eight tumors). Figure 3 demonstrates abnormal
migration patterns in two samples from tumor DNA
(PO49 and PO52, boxed). In both samples, there
was an abnormal conformer in two regions: 2.2 and
3. Sequencing the two samples with region 2.2
abnormal conformers revealed a Ser to Arg substi-
tution at codon 31. This substitution has been pre-
viously described as a polymorphism, x2’17 The same
two samples were sequenced for region 3. Both were
found to have a C-T transition at position 590
in the 3’ untranslated region of the p21 gene. This
change has also been described previously
18 and is
likely to be a polymorphism. No additional changes
were detected. However, the presence of both the
polymorphisms on the same allele has not been
observed previously. Thus, no random mutations
in the coding region of p21 were detected in this
series of RMS cell lines and tumor samples. SSCP
analysis of the promoter region for p21 (down-
stream of the TATA box, -30 bp from the tran-
scription start site) also revealed no mutations (data
not shown).
Suppression of tumor cellgrowth by p21
Since we failed to detect alterations in the primary
structure of the p21 gene in RMS, we sought to
analyze the functional integrity of the p21 pathway
in these tumors by forced expression of p21. Trans-
fection of p21 into the RMS cell line, RD, caused a
significant inhibition of cell colony formation as
measured in a clonogenicity assay (Fig. 4 and Table
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Fig. 4. Decreased colonyformation capacity ofRD cells transfected with p21. Following transfection, cells were maintained in the
presence ofhygromycin (500 #g ml- I, for a period of3 weeks, to select cell colonies containingfull length p21 cDNA or hygromycin
plasmid. The experiment was performed in triplicate. Differences between replicates did not exceed 15%.
Table 2. Inhibition of cell proliferation in the RMS cell line RD by p21
Plasmid Vector p21 p21 AS Mutant p21
(A) Cell number 2.4 1.2 2.8 2.0
(B) Colony number 37 4 55 ND
Inhibition of cell proliferation in the RMS cell line RD by p21.
(A) Cell numbers ( 106 ml-1) determined by direct cell counting.
(B) Number of colonies in a clonogenicity assay.
Abbreviations: vector, PCEP4 vector carrying hygromycin resistance
gene only; p21, full-length wild-type p21 cDNA; AS, full-length wild-type
p21 cDNA in anti-sense orientation; mutant, full-length p21 cDNA with
a codon 63 mutation; ND, not done.Disruption of the MyoD/p21 pathway in RMS 139
a 10-fold lower number of colonies (n 4) when
compared to the controls, represented by cells trans-
fected with vector alone (n- 37) or with anti-sense
p21 (n 55). (Expression of the p21 protein in the
transfected cells was confirmed by Western blot
analysis (data not shown).)
Consistent with these results, the cells transfected
with p21 showed a lower proliferative rate as deter-
mined by direct counting of cells derived from a
pool of colonies after trypsinization (Table 2).
Transfection with the mutant p21 had a lesser
growth inhibitory effect than transfection with wild-
type p21.
Discussion
Several lines of evidence point to an important role
played by the p21 protein in the process of normal
muscle cell differentiation. It was initially shown
that differentiated skeletal muscle cells express high
levels of the hypophosphorylated form of the
retinoblastoma (RB) protein, 19’2 and that loss ofRB
prevented G1 arrest in differentiated muscle
cells.21’2 CDK-mediated inactivation ofRB through
phosphorylation causes cells to enter the cell cycle
and proliferate.
3 By inhibiting the CDK’s, p21
induces cell-cycle arrest and inhibits cell prolifera-
tion. Subsequent studies showed that, in developing
skeletal muscle cells, arrest of cell proliferation is
associated with increased expression of p21. Fur-
thermore, MyoD, a member of the family of myo-
genic basic HLH proteins involved in induction of
muscle-differentiation specific genes, can induce
expression of p21. Consistent with this observation,
we also identified several CACGTG sites in the
regulatory region of p21.
8 Thus, p21 appears to be
involved in the coupling of the two processes of cell
proliferation arrest and terminal differentiation in
skeletal muscle cells.3
Since RMS is a tumor of primitive skeletal muscle
cells which undergo uncontrolled proliferation and
fail to differentiate terminally into normal skeletal
muscle, we chose to examine p21 status in these
tumors. In normal skeletal muscle cells, expression
of MyoD, and other muscle-specific genes, leads to
terminal differentiation and growth arrest, associ-
ated with induction ofp21 expression. Expression of
MyoD is also seen in the majority of cases of RMS,
irrespective of their histology.
4 Tonin et al.5 inves-
tigated the expression of several muscle-specific
genes in RMS of both embryonal and alveolar sub-
types. Their data suggest that RMS tumors regard-
less of histological features expressed MyoD 1. In the
data we present (Table 1) the levels of MyoD1
expression vary in RMS-independent histology.
Immunohistochemical analysis of MyoD 1
expression in 33 RMS samples reported by Wang et
al.
6 again demonstrated no significant differences in
the expression of MyoD 1 with respect to histologi-
cal subtypes. Thus, it appears certain that the
MyoD 1 expression is an invariant marker of RMS.
However, the expression ofMyoD in RMS does not
lead to proliferation arrest or to differentiation,
implying that, in these cells, the MyoD pathway is
functionally abnormal. This notion is supported by
previous studies which showed that MyoD obtained
from RMS was deficient in transactivation. Thus,
the question arose whether MyoD from RMS can
transactivate p21. We found that RMS cell lines and
tumors that express very high levels ofMyoD fail to
express p21, suggesting an inability of MyoD in
RMS to transactivate p21. RMS tumors that express
p21, however, express low levels of MyoD. These
results strongly suggest that the endogenous MyoD/
p21 pathway in these cells is abnormal, and is
unable to induce a cell-cycle arrest or promote
differentiation. This hypothesis is supported by the
finding that forced expression of wild-type p21 in
the transfected RD cell line, which expresses a high
endogenous level of p21, causes a marked inhibition
of cell proliferation. This suggests that the endoge-
nous p21 pathway in the RD cells is in some way
compromised. Since the defect can be overcome by
forced expression of exogenous p21, one may infer
that pathways downstream of p21 are intact.
To determine if the defect in p21 in RD cells and
in other RMS cells is the result of mutations in p21,
we performed an SSCP analysis to detect mutation
in the coding region of the p21 gene. Similar to
studies in other tumors, the analysis revealed no
mutations, suggesting that the putative defect in p21
in RMS is not due to primary structural alterations.
It is possible that SSCP analysis may have missed
some sequence changes;
7 however, our ability to
detect polymorphic changes would suggest that this
is not the case. Our data represent the first report on
p21 mutation analysis in RMS, and the absence of
p21 mutations in this tumor will need confirmation
with larger sample numbers. However, the absence
of mutations in the p21 gene is not unusual. Analy-
ses of the p21 coding region in a large number of
tumors of varying histologies have failed to reveal
mutations in this gene,18’8 with rare exceptions,
suggesting that a role for p21 in tumorigenesis may
involve mechanisms distinct from mutations.
18
Interestingly, we found an inverse correlation
between the expression of p21 and the expression of
MyoD. Cell lines and tumors expressing high p21
levels had a very low level ofMyoD expression and,
conversely, those cell lines and tumors with a high
MyoD levels expressed little or no p21. This may
imply that the normal process of cell-cycle arrest
and terminal differentiation in skeletal muscle cells
requires a cooperative action of p21 and MyoD.
Indeed, studies in RMS cells have shown that these
cells are deficient in a factor required for MyoD
activity. Formation of heterokaryons between RMS
cells and fibroblasts has been shown to restore the
ability of the RMS cells to differentiate into muscle
cells.
7 p21 may be the factor necessary for MyoD-140 M. Weintraub et al.
driven muscle cell differentiation, and its functional
abnormality in RMS cells, as shown in our experi-
ments, may explain the paradox of differentiation
failure in the face of high MyoD expression in RMS.
Our results suggest that the concurrent expression
of both MyoD and p21 may be necessary for the
integrity of the differentiation pathway in skeletal
muscle cells. Thus, the mutually exclusive
expression of MyoD and p21 in RMS suggests that
there are at least two distinct pathways of RMS
pathogenesis. In one group of tumors, p21 is
expressed at high levels but, despite this, is unable
to induce cell-cycle arrest, probably because the p21
in this group is compromised. Based on the results
of our sequence analysis, it seems unlikely that this
compromise is the result of a defect in the structural
integrity of p21. However, several studies have sug-
gested that there are at least two functionally dis-
tinct forms of cyclin-CDK kinase and p21
complexes. In one, the kinase is still active, while in
the other, p21 inhibits the kinase activity,z9’3
Recent data (Harlow, personal communication,
1995) suggest that the formation of these two func-
tional complexes may actually be based on the
amount of p21 present in the complex. Thus, when
present at high levels, p21 would form an inhibitory
complex. In our experiments, over-expression of
exogenous p21 in RMS cells that already express
high levels of endogenous p21 did indeed cause
growth arrest. Thus, one possible mechanism by
which endogenous p21 causes growth arrest in RMS
cells may be related to the stoichiometric compo-
sition of the cyclin-CDK-p21 complex, rendering
the complex non-functional with respect to cell-
cycle arrest. Increasing p21 levels in these cells by
transfecting a p21 expression vector probably allows
for a shift of the cyclin-CDK-p21 active complex to
an inhibitory statemresulting in the arrest of prolif-
eration. MyoD levels in this group of tumors are low
to undetectable. This, in conjunction with a catalyt-
ically active endogenous CDK-cyclin-p21 complex,
may also be related to the differentiation failure of
these cells. A second group of RMSs express high
levels of MyoD, but, in contrast to normal muscle,
this expression fails to induce p21 and, presumably,
to cause cell-cycle arrest. It is possible that the
normal cascade of growth arrest and induction of
terminal differentiation in skeletal muscle cells
requires the cooperative action of both MyoD and
p21, and it is this cooperative effect which is defec-
tive in RMS.
We found no association between the integrity of
the p53 gene in these cells and the level of p21
expression. In both tumors and cell lines, p21
expression varied between high and low in samples
with wild-type or mutant p53. This suggests that the
expression of p21 in these cells is independent of
p53. This observation is in agreement with studies
in mice embryos where the expression of p21 during
terminal differentiation is also p53 independent.
1
p21 can inhibit cell proliferation by at least two
distinct mechanisms: inhibition of CDK’s and direct
binding to PCNA.
31 Indeed, p21 has previously
been shown to suppress growth of tumor cell lines.
32
Furthermore, forced expression of p21 has been
shown to reverse the abnormal proliferation of
embryonal fibroblasts transformed by various onco-
genes.
33 Our results support the notion that p21
plays a critical role in the normal differentiation
pathway of skeletal muscle cells. In addition, our
study suggests that targeted over-expression of p21
in RMS cells may correct an important biochemical
defect in these cells and thus make RMS a suitable
tumor for new modalities of therapy with p21.
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